From dogma to data: charting a path forward for clinico-immunological research in Ethiopian cutaneous leishmaniasis

Read full text
Authors: Thao‐Thy Pham, Saskia van Henten, Mikias Woldetensay, Mezgebu Silamsaw Asres, Eleni Ayele, Paul M. Kaye, Malgorzata A. Domagalska, Jean-Claude Dujardin, Johan van Griensven, Wim Adriaensen, Mezgebu Silamsaw Asres, Eleni Ayele
+48 more Helina Fikre, Yonael Mulat, Tigist Mekonnen, Mekibib Kassa, Tadfe Bogale, Asnakew Engidaw Mereed, Tadele Mulaw, Roma Melkamu, Arega Yeshanew, Aman Mossa, Zemeney Mulugeta, Dilargachew Dessie Dawit, Aschalew Tamiru, Desalegn Adane, Saba Atnafu, Jemal Yasin, Abiy Ayele Angelo, Yetemwork Aleka, Hana Yohannes, Helen Terefe, Mikias Woldetensay, Abebe Sinknew Seid, Mesfin Malede Nigussie, Anemut Leykun Ayele, Beza Tesfalem, Tesfaye Ketema, Mengistu Tilaye Belay, Seidu Biresaw, Getachew Yenus Aman, Paul M. Kaye, Nidhi Sharma Dey, Shoumit Dey, Ron M. A. Heeren, Benjamin Baluff, Isabeau Vermeulen, Jianhua Cao, Filip Thiessen, Jean-Claude Dujardin, Malgorzata A. Domagalska, Kaoutar Choukri, Pieter Monsieurs, Johan van Griensven, Saskia van Henten, Myrthe Pareyn, Wim Adriaensen, Thao‐Thy Pham, Nicky de Vrij, Anke Van Hul
Cited by: 2
References: 37

Abstract

BACKGROUND: Rooted in long-standing assumptions and adapted from classifications mainly used for Latin American cutaneous leishmaniasis (CL), the nationally recommended clinical categories in Ethiopia for CL remain limited to localized cutaneous leishmaniasis (LCL), mucocutaneous leishmaniasis (MCL), and diffuse cutaneous leishmaniasis (DCL). However, these categories are associated with immune mechanisms which have not been validated in the Ethiopian context and thus risk misrepresenting the true clinical and immunopathological diversity. In this opinion piece, we will therefore outline key knowledge gaps and challenges in current clinico-immunological research on Ethiopian CL. MAIN BODY: In Ethiopia, Leishmania aethiopica is often assumed as the causative agent of these 'LCL', 'MCL' and 'DCL' forms, yet significant gaps in knowledge urge caution. For example, adoption of this 'LCL', 'MCL' and 'DCL' terminology and the associated immune mechanisms has led to inconsistent results. Most immunological studies on Ethiopian CL have focused on peripheral blood, resulting in little information about immune processes in the lesion, the original site of infection. Adding to the complexity, other species (including L. major, L. donovani and L. tropica as well as L. aethiopica hybrids) also circulate, with reports of Leishmania RNA virus co-infection. To address these challenges, we propose a multidimensional approach that combines standardized clinical documentation with appropriate lesion and blood sampling for in-depth profiling of both immune responses and parasite diversity. Adopting this holistic approach will require inclusive (inter)national collaborations with a focus on promoting equitable biobank and data sharing which will strengthen local research capacities. CONCLUSIONS: By addressing the main challenges and knowledge gaps in current clinico-immunological research through a multidimensional approach, this opinion aims to provide the tools to achieve a better and unbiased understanding of the immunopathogenesis of Ethiopian CL, a severe yet under-investigated disease. Such progress is essential for improving CL management in Ethiopia and aligns with the World Health Organization priority on controlling CL.

Fields of Study & Subjects

Research on Leishmaniasis Studies Eosinophilic Disorders and Syndromes Trypanosoma species research and implications

Publication details

Journal / source
Infectious Diseases of Poverty
Publisher
Springer Science and Business Media LLC
Volume
15
Issue
1
Pages
10–10
Publication date
16 January 2026
Language
EN